What is the efficacy and role of Rozelixizumab?

Rozanolixizumab (Rozanolixizumab) is a recombinant humanized monoclonal antibody mainly used to treat diseases related to excessive immune system response, especially those involving immune-mediated neurological diseases. The drug relieves diseases caused by immune factors called autoantibodies by specifically targeting and inhibiting them.

The main mechanism of action of roselixizumab is by inhibiting the interaction between immunoglobulinG (IgG) and Fc receptors in the immune system. IgG antibodies are an important immune factor in the human immune system and play a key role in a variety of immune responses. However, in some autoimmune diseases, excessive or abnormal IgG antibodies attack the body's own tissues and organs, leading to various diseases. By inhibiting the binding of IgG antibodies to Fc receptors, roselixizumab can reduce the excessive activation of immune responses and thereby control the progression of the disease.

Currently, roselixizumab is mainly used to treat a type of neuroimmune disease called"Myasthenia Gravis, MG; rare disease). Myasthenia gravis is a disease in which the immune system attacks signaling between nerves and muscles, causing muscle weakness that may affect breathing and swallowing in severe cases. By reducing these abnormal immune responses, roselixizumab significantly improves patients' symptoms, especially in those who have not responded well to other immunotherapies.

In general, roselixizumab, as an immunomodulator, mainly reduces the symptoms of immune-mediated neurological diseases by regulatingthe activity of IgG antibodies. It provides a new treatment option for many patients, especially those who are refractory to traditional treatments, and its efficacy and mechanism of action make it one of the important drugs in the field of immune disease treatment.

Reference materials:https://www.drugs.com/rystiggo.html